Yes I suspect your line of thinking is similar to my own. PR is a salesman and would expect big pharma BDMs to the bridge the gap within their distribution channels. They will have supporting material no doubt from the supporting P3 substreams now proposed. Nevertheless BDMs and word of mouth on PPS's being a DMOAD may still be of limited relevance on any future deal given its not why it will be approved for use. So how PPS is initially pitched (sold) becomes the billion dollar question.
Blind spots, page-3
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.015(6.98%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 20.0¢ | $201.6K | 994.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 429247 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 13806 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |